Liu Zhenteng, Liu Xuemei, Wang Meimei, Zhao Huishan, He Shunzhi, Lai Shoucui, Qu Qinglan, Wang Xinrong, Zhao Dongmei, Bao Hongchu
Department of Reproductive Medicine, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, China.
Front Physiol. 2022 Apr 27;13:841437. doi: 10.3389/fphys.2022.841437. eCollection 2022.
To assess the prevalence of displaced window of implantation (WOI) in infertile women, and the clinical utility of personalized embryo transfer (pET) guided by the endometrial receptivity array/analysis (ERA) on IVF/ICSI outcomes. The protocol was registered at Prospero: CRD42020204237. We systematically searched all published English literature related to the prevalence of WOI displacement and ongoing pregnancy rate/live birth rate in the overall good-prognosis infertile patients (GPP) and/or repeated implantation failure (RIF) patients undergoing IVF/ICSI-ET cycles after ERA test until August 2021. 11 published studies were enrolled in the final analysis. The estimate of the incidence of WOI displacement based on ERA was 38% (95%CI 19-57%) in GPP and 34% (95%CI 24-43%) in RIF, respectively. There was no difference in OPR/LBR between patients undergoing routine ET without ERA test and those who following pET with ERA (39.5 vs. 53.7%, OR 1.28, = 0.49, 95%CI 0.92-1.77, = 0%) in relative GPP. Notably, the meta-analysis revealed that OPR/LBR of patients with RIF undergoing pET who had non-receptive ERA increased to the level of to those undergoing sET with receptive ERA (40.7 vs.49.6%, OR 0.94, = 0.85, 95%CI 0.70-1.26, = 0%). Considering the approximately one third of infertile women could suffered from displaced WOI, the ERA test emerged as a promising tool. Although the present meta-analysis demonstrates that patients with general good-prognosis may not benefit from ERA, pET guided by ERA significantly increases the chances of pregnancy for non-receptive patients with RIF of endometrial origin.
评估不孕女性中种植窗(WOI)移位的发生率,以及子宫内膜容受性阵列/分析(ERA)指导下的个性化胚胎移植(pET)对体外受精/卵胞浆内单精子注射(IVF/ICSI)结局的临床应用价值。该方案已在国际前瞻性系统评价注册库(Prospero)注册:CRD42020204237。我们系统检索了截至2021年8月所有已发表的英文文献,这些文献涉及在接受ERA检测后的体外受精/卵胞浆内单精子注射-胚胎移植(IVF/ICSI-ET)周期中,总体预后良好的不孕患者(GPP)和/或反复种植失败(RIF)患者中WOI移位的发生率以及持续妊娠率/活产率。最终纳入11项已发表的研究进行分析。基于ERA的GPP中WOI移位发生率估计为38%(95%置信区间19 - 57%),RIF中为34%(95%置信区间24 - 43%)。在相对GPP中,未进行ERA检测而接受常规胚胎移植的患者与接受ERA指导下pET的患者之间的着床率/活产率无差异(39.5%对53.7%,比值比1.28,P = 0.49,95%置信区间0.92 - 1.77,I² = 0%)。值得注意的是,荟萃分析显示,ERA结果为非容受性的RIF患者接受pET后的着床率/活产率提高到了ERA结果为容受性的患者接受选择性胚胎移植(sET)后的水平(40.7%对49.6%,比值比0.94,P = 0.85,95%置信区间0.70 - 1.26,I² = 0%)。考虑到约三分之一的不孕女性可能存在WOI移位,ERA检测成为一种有前景的工具。尽管目前的荟萃分析表明总体预后良好的患者可能无法从ERA中获益,但ERA指导下的pET显著增加了子宫内膜源性RIF的非容受性患者的妊娠机会。